India’s First Alzheimer’s Disease-Modifying Therapy Is Now Available — What It Means for Patients and Hospitals
For decades, treating Alzheimer’s disease in India meant managing symptoms. Medications like rivastigmine and donepezil could slow cognitive decline for a period, but nothing available in the Indian market could actually target the disease process itself — the accumulating amyloid plaques in the brain that are understood to drive the neurodegeneration underlying Alzheimer’s. That changed […]
Named Patient Program vs Patient Assistance Program — What Indian Consumers Need to Know
Two programs. Two very different purposes. And yet, for patients and families navigating serious illness in India, the terms Named Patient Program and Patient Assistance Program come up in the same conversations, recommended by the same doctors, and processed through the same hospital pharmacy counters — which is exactly why so many people end up […]
The Real Cost of Sourcing Imported Medicines From the Wrong Distributor
Nobody in hospital procurement sets out to source from the wrong distributor. It usually starts with a budget conversation, a vendor offering a price that seems too good to ignore, or a time-pressured order where the usual channel isn’t available. The decision gets made quickly, the medicine arrives, and for a while nothing seems wrong. […]
Trodelvy (Sacituzumab Govitecan) in India: A Sourcing Guide for Hospitals Treating Triple-Negative Breast Cancer
Trodelvy has become an increasingly requested medicine among Indian oncology centres treating triple-negative breast cancer, a subtype known for its aggressive course and historically limited treatment options. As demand for this antibody-drug conjugate grows, hospital procurement teams and pharmacies are asking more practical questions — less about the science, which is well established in oncology […]
Zoladex (Goserelin) Injection in India 2026: Complete Guide to Uses, Dosing, and Sourcing for Hospitals and Oncology Centres
Goserelin, sold under the brand name Zoladex, has been a cornerstone of hormone therapy for more than three decades, and it remains one of the most consistently prescribed LHRH agonists across Indian oncology and gynaecology practices in 2026. Despite how established the molecule is, hospital pharmacists and procurement teams still raise the same set of […]
How to Verify That Your Imported Cancer Medicine Is Genuine — A Safety Guide for Hospital Pharmacists in India 2026
In May 2026, Delhi Police busted a counterfeit medicine racket worth nearly Rs 10 crore — four people arrested for manufacturing and supplying fake life-saving drugs for cancer and liver disease. Fake medicines, packaging equipment, forged labels — all recovered from an operation supplying hospitals across multiple states. Weeks earlier in April 2026, a detailed […]
Palbociclib, Ribociclib and Abemaciclib in India 2026 — Which CDK4/6 Inhibitor Is Right for Your Patient?
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by a class of medicines called […]
Lutetium-177 PSMA Therapy for Prostate Cancer in India — Who Qualifies, How It Works, and Where to Access It in 2026
For most of the past two decades, Indian men diagnosed with advanced prostate cancer had a fairly narrow set of treatment options — hormone therapy, chemotherapy if the cancer progressed, and more recently oral targeted medicines like Enzalutamide (Glenza) and Abiraterone (Abirapro). These are genuinely effective medicines, but they work for a limited time in […]
Enhertu and the ADC Revolution — Why Antibody-Drug Conjugates Are the Most Important Development in Cancer Treatment in 2026
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication and was being described by […]
Ozempic vs Mounjaro vs Wegovy in India 2026 — Which GLP-1 Should Your Patient Choose?
India’s diabetes and obesity treatment landscape changed dramatically in March 2026. Novo Nordisk’s core Indian patent for semaglutide expired on March 20, 2026 — within hours, a wave of Indian pharmaceutical companies launched their own versions at dramatically lower prices. Branded Ozempic costs ₹8,800–₹11,175 per month in India, while the cheapest generic is now available […]
